SG11201700734RA - Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them - Google Patents
Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing themInfo
- Publication number
- SG11201700734RA SG11201700734RA SG11201700734RA SG11201700734RA SG11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA SG 11201700734R A SG11201700734R A SG 11201700734RA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- tetrahydroquinoline
- triazol
- fluorophenyl
- carboxylate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031521P | 2014-07-31 | 2014-07-31 | |
| PCT/US2015/042867 WO2016019125A1 (en) | 2014-07-31 | 2015-07-30 | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700734RA true SG11201700734RA (en) | 2017-02-27 |
Family
ID=55218310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700734RA SG11201700734RA (en) | 2014-07-31 | 2015-07-30 | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20170217921A1 (en) |
| EP (1) | EP3174855B1 (en) |
| JP (4) | JP2017523243A (en) |
| KR (1) | KR20170038850A (en) |
| CN (1) | CN107155326B (en) |
| AU (1) | AU2015296289B2 (en) |
| BR (1) | BR112017001977A2 (en) |
| CA (1) | CA2956714A1 (en) |
| EA (1) | EA201790290A1 (en) |
| ES (1) | ES2947501T3 (en) |
| IL (1) | IL250365B (en) |
| MX (1) | MX2017001416A (en) |
| SG (1) | SG11201700734RA (en) |
| TW (1) | TWI693214B (en) |
| WO (1) | WO2016019125A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102171214B (en) | 2008-08-06 | 2015-06-24 | 生物马林药物股份有限公司 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| HUE030794T2 (en) | 2010-02-08 | 2017-06-28 | Medivation Technologies Inc | Processes of synthesizing dihydropyridophthalazinone derivatives |
| AR083502A1 (en) | 2010-10-21 | 2013-02-27 | Biomarin Pharm Inc | TOSILADA SALT OF (8S, 9R) -5-FLUORO-8- (4-FLUOROFENIL) -9- (1-METHYL-1H-1,2,4-TRIAZOL-5-IL) -8,9-DIHIDRO-2H -PIRIDO [4,3,2-DE] FTALAZIN-3 (7H) -ONA CRISTALINA |
| US9708319B1 (en) * | 2016-06-13 | 2017-07-18 | Yong Xu | Synthesis of PARP inhibitor talazoparib |
| US20200254091A1 (en) | 2017-10-13 | 2020-08-13 | Merck Patent Gmbh | Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist |
| TW201938165A (en) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | Methods and combination therapy to treat cancer |
| EP3876940A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinations for treating cancer |
| CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
| IL302889A (en) | 2020-11-13 | 2023-07-01 | Pfizer | Talazoparib soft gelatin capsule dosage form |
| EP4256088A1 (en) | 2020-12-07 | 2023-10-11 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| BR112023018906A2 (en) | 2021-03-24 | 2023-10-10 | Astellas Pharma Inc | COMBINATION OF TALAZOPARIB AND AN ANTIANDROGEN FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH MUTATION IN THE DDR GENE |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| TW202425975A (en) | 2022-10-02 | 2024-07-01 | 美商輝瑞大藥廠 | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| TW202425976A (en) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5852253A (en) * | 1981-09-21 | 1983-03-28 | Tanabe Seiyaku Co Ltd | P-hydroxyphenylglycine-alpha-phenylethanesulfonic acid salt and its optical resolution |
| US4415504A (en) * | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS63192753A (en) * | 1987-02-05 | 1988-08-10 | Otsuka Pharmaceut Co Ltd | Optical resolution of tetrahydroquinoline derivative |
| JPH08322591A (en) * | 1995-06-02 | 1996-12-10 | Sumitomo Pharmaceut Co Ltd | Production of optically pure 1,2,3,4-tetrahydroquinoline-2-acetic acid esters by optical resolution method |
| JP2010536807A (en) * | 2007-08-22 | 2010-12-02 | ４エスツェー アクチェンゲゼルシャフト | Indropyridine as an inhibitor of kinesin spindle protein (EG5) |
| CN101298452A (en) * | 2008-06-30 | 2008-11-05 | 南京华威医药科技开发有限公司 | Preparing methods and uses of S-(-)-nadifloxacin and water soluble salt thereof |
| CN102171214B (en) | 2008-08-06 | 2015-06-24 | 生物马林药物股份有限公司 | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| BRPI0914556A2 (en) * | 2008-08-12 | 2015-08-04 | Boehringer Ingelheim Int | Process for the preparation of cycloalkyl substituted piperazine compounds |
| HUE030794T2 (en) * | 2010-02-08 | 2017-06-28 | Medivation Technologies Inc | Processes of synthesizing dihydropyridophthalazinone derivatives |
| AR083502A1 (en) * | 2010-10-21 | 2013-02-27 | Biomarin Pharm Inc | TOSILADA SALT OF (8S, 9R) -5-FLUORO-8- (4-FLUOROFENIL) -9- (1-METHYL-1H-1,2,4-TRIAZOL-5-IL) -8,9-DIHIDRO-2H -PIRIDO [4,3,2-DE] FTALAZIN-3 (7H) -ONA CRISTALINA |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
-
2015
- 2015-07-30 US US15/329,549 patent/US20170217921A1/en not_active Abandoned
- 2015-07-30 MX MX2017001416A patent/MX2017001416A/en unknown
- 2015-07-30 SG SG11201700734RA patent/SG11201700734RA/en unknown
- 2015-07-30 CA CA2956714A patent/CA2956714A1/en not_active Abandoned
- 2015-07-30 ES ES15826816T patent/ES2947501T3/en active Active
- 2015-07-30 WO PCT/US2015/042867 patent/WO2016019125A1/en active Application Filing
- 2015-07-30 EA EA201790290A patent/EA201790290A1/en unknown
- 2015-07-30 EP EP15826816.9A patent/EP3174855B1/en active Active
- 2015-07-30 BR BR112017001977A patent/BR112017001977A2/en not_active Application Discontinuation
- 2015-07-30 JP JP2017526474A patent/JP2017523243A/en not_active Withdrawn
- 2015-07-30 CN CN201580052825.0A patent/CN107155326B/en active Active
- 2015-07-30 KR KR1020177004847A patent/KR20170038850A/en active IP Right Grant
- 2015-07-30 AU AU2015296289A patent/AU2015296289B2/en active Active
- 2015-07-31 TW TW104124989A patent/TWI693214B/en active
-
2017
- 2017-01-30 IL IL250365A patent/IL250365B/en active IP Right Grant
-
2018
- 2018-09-11 US US16/128,406 patent/US20190106401A1/en not_active Abandoned
-
2020
- 2020-04-02 JP JP2020067069A patent/JP2020125303A/en not_active Withdrawn
- 2020-08-10 US US16/989,841 patent/US20210094930A1/en not_active Abandoned
-
2022
- 2022-06-03 JP JP2022090681A patent/JP2022116288A/en not_active Withdrawn
-
2024
- 2024-06-14 JP JP2024096810A patent/JP2024123096A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017523243A (en) | 2017-08-17 |
| IL250365A0 (en) | 2017-03-30 |
| EA201790290A1 (en) | 2017-07-31 |
| TW201617319A (en) | 2016-05-16 |
| EP3174855A4 (en) | 2018-03-21 |
| TWI693214B (en) | 2020-05-11 |
| JP2022116288A (en) | 2022-08-09 |
| JP2020125303A (en) | 2020-08-20 |
| BR112017001977A2 (en) | 2017-11-21 |
| CA2956714A1 (en) | 2016-02-04 |
| IL250365B (en) | 2021-02-28 |
| US20170217921A1 (en) | 2017-08-03 |
| JP2024123096A (en) | 2024-09-10 |
| ES2947501T3 (en) | 2023-08-10 |
| WO2016019125A1 (en) | 2016-02-04 |
| US20190106401A1 (en) | 2019-04-11 |
| CN107155326A (en) | 2017-09-12 |
| EP3174855A1 (en) | 2017-06-07 |
| CN107155326B (en) | 2021-03-05 |
| EP3174855B1 (en) | 2023-05-10 |
| KR20170038850A (en) | 2017-04-07 |
| MX2017001416A (en) | 2017-05-19 |
| AU2015296289B2 (en) | 2020-02-27 |
| AU2015296289A1 (en) | 2017-03-02 |
| US20210094930A1 (en) | 2021-04-01 |
| NZ728634A (en) | 2021-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250365B (en) | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them | |
| HUE054964T2 (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| HK1231377A1 (en) | Pharmaceutical composition containing quinoline derivative or salt thereof, and preparation method therefor | |
| HK1251551A1 (en) | Azetidine derivative, preparation method therefor, and use thereof | |
| IL289099A (en) | Methods for the storage of whole blood, and compositions thereof | |
| IL247833A0 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| EP3385262A4 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| ZA201606386B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| EP3115361A4 (en) | Heterocyclic compounds, and preparation method and use thereof | |
| PT3388420T (en) | Quinoline compounds, preparation method thereof, and use thereof as urate transporter inhibitor drug | |
| EP3109240A4 (en) | Triazine compound and use thereof for medical purposes | |
| PT3527552T (en) | Fused tricyclic -amino acid derivative, preparation method therefor, and medical use thereof | |
| SG11201709414XA (en) | Powdered titanium oxide, method for the production thereof, and use thereof | |
| HK1250662A1 (en) | Immunogenic fusion proteins for the treatment of cancer | |
| EP3261580A4 (en) | Dental implant identification system | |
| SI3331583T1 (en) | Medical implant based on nanocellulose | |
| EP3556761A4 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| EP3171840A4 (en) | Improved medical implant | |
| EP3118244A4 (en) | Novel cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same | |
| HRP20200104T8 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| MX369506B (en) | Metal salt compositions. | |
| GB201714060D0 (en) | Method for preparing itraconazole preparation | |
| EP3199526A4 (en) | Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof | |
| EP3231455A4 (en) | Biocompatible composition and method for preparing same | |
| EP3127903A4 (en) | 2,2'-tandem dithiazole compound, preparation method therefor, and use thereof |